Elizabeth Barrett is President and Chief Executive Officer of UroGen Pharma Ltd. (URGN). The company reported total compensation of $4,310,624 for fiscal year 2025.
| Salary | $855,590 |
|---|---|
| Bonus | $774,066 |
| Stock awards | $2,122,211 |
| Option awards | $0 |
| Non-equity incentive plan | $516,263 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $42,494 |
| Total | $4,310,624 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure UroGen Pharma Ltd. filed April 30, 2026, accession 0001437749-26-014237.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $855,590 | $774,066 | $2,122,211 | $0 | $516,263 | $0 | $42,494 | $4,310,624 |
| FY2024 | Chief Executive Officer | $826,013 | — | $2,751,111 | — | $529,981 | — | $42,753 | $4,149,858 |
Totals as disclosed in each year's own compensation disclosure for UroGen Pharma Ltd..
| Peer-group chief executive median | $4,735,016 |
|---|---|
| Difference from that median | $-424,392 |
| Percentile within the disclosed peer group | 35th |
| Peers with a disclosed figure | 17 |
Medians and percentiles are computed across the peer group UroGen Pharma Ltd. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Elizabeth Barrett this page | President and Chief Executive Officer | $4,310,624 |
| Jason Smith | General Counsel and Chief Compliance Officer | $1,198,618 |
| Mark Schoenberg | Chief Medical Officer | $1,170,640 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full UroGen Pharma Ltd. compensation brief.
Elizabeth Barrett's compensation sits inside UroGen Pharma Ltd.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.